Renal cell cancer patients with brain metastatic disease generally have poor prognosis. Treatment options include surgery, radiotherapy, targeted therapy or best supportive care with respect to disease burden, patient preference and performance status. In the present case report the radiotherapy technique combining whole brain radiotherapy with hippocampal sparing (hippocampal avoidance whole brain radiotherapy HA-WBRT) and hypofractionated stereotactic radiotherapy (SRT) of the brain metastases is performed in a patient with metastatic renal cell carcinoma. HA-WBRT was administered to 30 Gy in 10 fractions with sparing of the hippocampal structures and SRT of 21 Gy in 3 fractions to brain metastases which has preceded the HA-WBRT. Two single arc volumetric modulated arc radiotherapy (VMAT) plans were prepared using Monaco planning software. The HA-WBRT treatment plan achieved the following results: D2=33.91 Gy, D98=25.20 Gy, D100=14.18 Gy, D50=31.26 Gy. The homogeneity index was calculated as a deduction of the minimum dose in 2% and 98% of the planning target volume (PTV), divided by the minimum dose in 50% of the PTV. The maximum dose to the hippocampus was 17.50 Gy and mean dose was 11.59 Gy. The following doses to organs at risk (OAR) were achieved: Right opticus Dmax, 31.96 Gy; left opticus Dmax, 30.96 Gy; chiasma D max, 32,76 Gy. The volume of PTV for stereotactic radiotherapy was 3,736 cm3, with coverage D100=20.95 Gy and with only 0.11% of the PTV being irradiated to dose below the prescribed dose. HA-WBRT with SRT represents a feasible technique for radiotherapy of brain metastatic disease, however this technique is considerably demanding on departmental equipment and staff time/experience.

Department of Neurosurgery Faculty of Medicine and Dentistry Palacky University Olomouc 77900 Czech Republic

Department of Oncology Faculty of Medicine and Dentistry Palacky University Olomouc 77900 Czech Republic

Department of Oncology Faculty of Medicine and Dentistry Palacky University Olomouc 77900 Czech Republic; Institute of Molecular and Translational Medicine Faculty of Medicine and Dentistry Palacky University University Hospital in Olomouc Olomouc 77900 Czech Republic; Toxicogenomics Unit National Institute of Public Health Prague 10042 Czech Republic

Zobrazit více v PubMed

Culine S, Bekradda M, Kramar A, Rey A, Escudier B, Droz JP. Prognostic factors for survival in patients with brain metastases from renal cell carcinoma. Cancer. 1998;83:2548–2553. doi: 10.1002/(SICI)1097-0142(19981215)83:12<2548::AID-CNCR21>3.3.CO;2-W. PubMed DOI

Escudier B, Porta C, Schmidinger M, Algaba F, Patard JJ, Khoo V, Eisen T, Horwich A. ESMO Guidelines Working Group: Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):iii49–iii56. doi: 10.1093/annonc/mdu259. PubMed DOI

Tsao MN, Rades D, Wirth A, Lo SS, Danielson BL, Gaspar LE, Sperduto PW, Vogelbaum MA, Radawski JD, Wang JZ, et al. Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): An American Society for Radiation Oncology evidence-based guideline. Pract Radiat Oncol. 2012;2:210–225. doi: 10.1016/j.prro.2011.12.004. PubMed DOI PMC

Minniti G, D'Angelillo RM, Scaringi C, Trodella LE, Clarke E, Matteucci P, Osti MF, Ramella S, Enrici RM, Trodella L. Fractionated stereotactic radiosurgery for patients with brain metastases. J Neurooncol. 2014;117:295–301. doi: 10.1007/s11060-014-1388-3. PubMed DOI

Kim YJ, Cho KH, Kim JY, Lim YK, Min HS, Lee SH, Kim HJ, Gwak HS, Yoo H, Lee SH. Single-dose versus fractionated stereotactic radiotherapy for brain metastases. Int J Radiat Oncol Biol Phys. 2011;81:483–489. doi: 10.1016/j.ijrobp.2010.05.033. PubMed DOI

Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, McKenna WG, Byhardt R. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997;37:745–751. doi: 10.1016/S0360-3016(96)00619-0. PubMed DOI

Nieder C, Marienhagen K, Geinitz H, Molls M. Validation of the graded prognostic assessment index for patients with brain metastases. Acta Oncol. 2009;48:457–459. doi: 10.1080/02841860802342390. PubMed DOI

Villà S, Weber DC, Moretones C, Mañes A, Combescure C, Jové J, Puyalto P, Cuadras P, Bruna J, Verger E, et al. Validation of the new graded prognostic assessment scale for brain metastases: A multicenter prospective study. Radiat Oncol. 2011;6:23. doi: 10.1186/1748-717X-6-23. PubMed DOI PMC

Nieder C, Andratschke NH, Geinitz H, Grosu AL. Diagnosis-specific graded prognostic assessment score is valid in patients with brain metastases treated in routine clinical practice in two European countries. Med Sci Monit. 2012;18:CR450–CR455. doi: 10.12659/MSM.883213. PubMed DOI PMC

International Commission on Radiation Units and Measurements: Prescribing, Recording and Reporting Photon Beam Therapy (Report 50) Bethesda: 1993.

International Commission on Radiation Units and Measurements: Prescribing, Recording and Reporting Photon Beam Therapy (Report 62) Bethesda: 1999.

International Commission on Radiation Units and Measurements: Prescribing, Recording and Reporting Intensity-Modulated Photon-Beam Therapy (IMRT) (ICRU Report 83) Washington: 2010.

Gondi V, Pugh SL, Tome WA, Caine C, Corn B, Kanner A, Rowley H, Kundapur V, DeNittis A, Greenspoon JN, et al. Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): A phase II multi-institutional trial. J Clin Oncol. 2014;32:3810–3816. doi: 10.1200/JCO.2014.57.2909. PubMed DOI PMC

Rades D, Bohlen G, Pluemer A, Veninga T, Hanssens P, Dunst J, Schild SE. Stereotactic radiosurgery alone versus resection plus whole-brain radiotherapy for 1 or 2 brain metastases in recursive partitioning analysis class 1 and 2 patients. Cancer. 2007;109:2515–2521. doi: 10.1002/cncr.22729. PubMed DOI

Karlovits BJ, Quigley MR, Karlovits SM, Miller L, Johnson M, Gayou O, Fuhrer R. Stereotactic radiosurgery boost to the resection bed for oligometastatic brain disease: Challenging the tradition of adjuvant whole-brain radiotherapy. Neurosurg Focus. 2009;27:E7. doi: 10.3171/2009.9.FOCUS09191. PubMed DOI

Kocher M, Soffietti R, Abacioglu U, Villà S, Fauchon F, Baumert BG, Fariselli L, Tzuk-Shina T, Kortmann RD, Carrie C, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: Results of the EORTC 22952–26001 study. J Clin Oncol. 2011;29:134–141. doi: 10.1200/JCO.2010.30.1655. PubMed DOI PMC

Iwadate Y, Namba H, Yamaura A. Whole-brain radiation therapy is not beneficial as an adjuvant therapy for brain metastases compared with localized irradiation. Anticancer Res. 2002;22:325–330. PubMed

Mintz A, Perry J, Spithoff K, Chambers A, Laperriere N. Management of single brain metastasis: A practice guideline. Curr Oncol. 2007;14:131–143. doi: 10.3747/co.2007.129. PubMed DOI PMC

Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K, Kenjyo M, Oya N, Hirota S, Shioura H, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: A randomized controlled trial. JAMA. 2006;295:2483–2491. doi: 10.1001/jama.295.21.2483. PubMed DOI

Tsao MN, Lloyd NS, Wong RK. Supportive Care Guidelines Group of Cancer Care Ontario's Program in Evidence-based Care: Clinical practice guideline on the optimal radiotherapeutic management of brain metastases. BMC Cancer. 2005;5:34. doi: 10.1186/1471-2407-5-34. PubMed DOI PMC

Khuntia D, Brown P, Li J, Mehta MP. Whole-brain radiotherapy in the management of brain metastasis. J Clin Oncol. 2006;24:1295–1304. doi: 10.1200/JCO.2005.04.6185. PubMed DOI

Soon YY, Tham IW, Lim KH, Koh WY, Lu JJ. Surgery or radiosurgery plus whole brain radiotherapy versus surgery or radiosurgery alone for brain metastases. Cochrane Database Syst Rev. 2014;3:CD009454. PubMed PMC

Kocher M, Maarouf M, Bendel M, Voges J, Müller RP, Sturm V. Linac radiosurgery versus whole brain radiotherapy for brain metastases. A survival comparison based on the RTOG recursive partitioning analysis. Strahlenther Onkol. 2004;180:263–267. doi: 10.1007/s00066-004-1180-y. PubMed DOI

Rades D, Schild SE. Do patients with a limited number of brain metastases need whole-brain radiotherapy in addition to radiosurgery? Strahlenther Onkol. 2012;188:702–706. doi: 10.1007/s00066-012-0093-4. PubMed DOI

Golden DW, Lamborn KR, McDermott MW, Kunwar S, Wara WM, Nakamura JL, Sneed PK. Prognostic factors and grading systems for overall survival in patients treated with radiosurgery for brain metastases: Variation by primary site. J Neurosurg. 2008;109(Suppl):S77–S86. PubMed

Kocher M, Wittig A, Piroth MD, Treuer H, Seegenschmiedt H, Ruge M, Grosu AL, Guckenberger M. Stereotactic radiosurgery for treatment of brain metastases. A report of the DEGRO working group on stereotactic radiotherapy. Strahlenther Onkol. 2014;190:521–532. doi: 10.1007/s00066-014-0648-7. PubMed DOI

Bates JE, Youn P, Peterson CR, III, Usuki KY, Walter KA, Okunieff P, Milano MT. Radiotherapy for brain metastases from renal cell carcinoma in the targeted therapy Era: The university of Rochester experience. Am J Clin Oncol. 2015 Feb 26; doi: 10.1097/COC.0000000000000186. (Epub ahead of print) PubMed DOI

Fokas E, Henzel M, Hamm K, Surber G, Kleinert G, Engenhart-Cabillic R. Radiotherapy for brain metastases from renal cell cancer: Should whole-brain radiotherapy be added to stereotactic radiosurgery? Analysis of 88 patients. Strahlenther Onkol. 2010;186:210–217. doi: 10.1007/s00066-010-2055-z. PubMed DOI

Rades D, Kueter JD, Hornung D, Veninga T, Hanssens P, Schild SE, Dunst J. Comparison of stereotactic radiosurgery (SRS) alone and whole brain radiotherapy (WBRT) plus a stereotactic boost (WBRT+SRS) for one to three brain metastases. Strahlenther Onkol. 2008;184:655–662. doi: 10.1007/s00066-008-1946-8. PubMed DOI

Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG, Arbuckle RB, Swint JM, Shiu AS, Maor MH, Meyers CA. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: A randomised controlled trial. Lancet Oncol. 2009;10:1037–1044. doi: 10.1016/S1470-2045(09)70263-3. PubMed DOI

Mizumatsu S, Monje ML, Morhardt DR, Rola R, Palmer TD, Fike JR. Extreme sensitivity of adult neurogenesis to low doses of X-irradiation. Cancer Res. 2003;63:4021–4027. PubMed

Collier TJ, Quirk GJ, Routtenberg A. Separable roles of hippocampal granule cells in forgetting and pyramidal cells in remembering spatial information. Brain Res. 1987;409:316–328. doi: 10.1016/0006-8993(87)90717-7. PubMed DOI

Raber J, Rola R, LeFevour A, Morhardt D, Curley J, Mizumatsu S, VandenBerg SR, Fike JR. Radiation-induced cognitive impairments are associated with changes in indicators of hippocampal neurogenesis. Radiat Res. 2004;162:39–47. doi: 10.1667/RR3206. PubMed DOI

Rades D, Kueter JD, Pluemer A, Veninga T, Schild SE. A matched-pair analysis comparing whole-brain radiotherapy plus stereotactic radiosurgery versus surgery plus whole-brain radiotherapy and a boost to the metastatic site for one or two brain metastases. Int J Radiat Oncol Biol Phys. 2009;73:1077–1081. doi: 10.1016/j.ijrobp.2008.05.035. PubMed DOI

Suh JH. Hippocampal-avoidance whole-brain radiation therapy: A new standard for patients with brain metastases? J Clin Oncol. 2014;32:3789–3791. doi: 10.1200/JCO.2014.58.4367. PubMed DOI PMC

Sahgal A, Larson D, Knisely J. Stereotactic radiosurgery alone for brain metastases. Lancet Oncol. 2015;16:249–250. doi: 10.1016/S1470-2045(14)71106-4. PubMed DOI

Langley RE, Stephens RJ, Nankivell M, Pugh C, Moore B, Navani N, Wilson P, Faivre-Finn C, Barton R, Parmar MK, Mulvenna PM. QUARTZ Investigators: Interim data from the Medical Research Council QUARTZ Trial: does whole brain radiotherapy affect the survival and quality of life of patients with brain metastases from non-small cell lung cancer? Clin Oncol (R Coll Radiol) 2013;25:e23–e30. doi: 10.1016/j.clon.2012.11.002. PubMed DOI

Prokic V, Wiedenmann N, Fels F, Schmucker M, Nieder C, Grosu AL. Whole brain irradiation with hippocampal sparing and dose escalation on multiple brain metastases: A planning study on treatment concepts. Int J Radiat Oncol Biol Phys. 2013;85:264–270. doi: 10.1016/j.ijrobp.2012.02.036. PubMed DOI

Ghia A, Tomé WA, Thomas S, Cannon G, Khuntia D, Kuo JS, Mehta MP. Distribution of brain metastases in relation to the hippocampus: Implications for neurocognitive functional preservation. Int J Radiat Oncol Biol Phys. 2007;68:971–977. doi: 10.1016/j.ijrobp.2007.02.016. PubMed DOI

Antonadou D, Coliarakis N, Paraskevaidis M, Athanasiou H, Sarris G, Synodinou M, Skarlatos I, Sagriotis A, Georgakopoulos G, Beroukas C, et al. Whole brain radiotherapy alone or in combination with temazolamide for brain metastases. A phase III study. Int J Radiat Oncol Biol Phys. 2002;54:93. doi: 10.1016/S0360-3016(02)03217-0. DOI

Incidence of Hippocampal Metastases: Laterality and Implications for Unilateral Hippocampal Avoiding Whole Brain Radiotherapy

Stereotactic radiotherapy in the treatment of local recurrences of esophageal cancer